HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features-Reference-Cited by-全球学者库

HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features

Published:2018-07-28 Issue:4 Volume:473 Page:413-423
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Park Jun Seok,Yoon Ghilsuk,Kim Hye Jin,Park Soo Yeun,Choi Gyu Seog,Kang Min Kyu,Kim Jong Gwang,Jang Jung-Sik,Seo An Na^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1007/s00428-018-2409-y/fulltext.html

Reference40 articles.

1. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013) Cancer genome landscapes. Science (New York, NY) 339(6127):1546–1558. https://doi.org/10.1126/science.1235122

2. Fakih MG (2015) Metastatic colorectal cancer: current state and future directions. J Clin Oncol 33(16):1809–1824. https://doi.org/10.1200/jco.2014.59.7633

3. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE (2015) The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 526(7572):263–267. https://doi.org/10.1038/nature14969

4. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L (2011) A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1(6):508–523. https://doi.org/10.1158/2159-8290.cd-11-0109

5. Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, Throsby M, Bertotti A, Trusolino L (2015) Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res 21(24):5519–5531. https://doi.org/10.1158/1078-0432.ccr-14-3066

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer;JNCI Cancer Spectrum;2023-10-10

2. Effect and imaging analysis of cetuximab combined with radiotherapy in patients with rectal carcinoma;Biotechnology and Genetic Engineering Reviews;2023-05-29

3. An Update on the Role of Immunohistochemistry in the Evaluation of Pancreatic/Liver/Gastrointestinal Luminal Tract Disorders;Archives of Pathology & Laboratory Medicine;2023-05-03

4. PIK3CAMutations as a Prognostic Factor in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy;Anticancer Research;2023-03-27

5. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria;Journal of Cancer Research and Clinical Oncology;2022-08-26